Purpose: Determine outcomes of positive crossmatch (PXM) renal transplant recipients that failed to convert to negative flow cytometry crossmatch (FCXM) despite desensitization.
Methods: All patients that underwent desensitization prior to a PXM transplant between 1/1/00 and 11/1/11 were identified for analysis. Patients who underwent transplantation despite failure to convert to negative FCXM were identified as the PXM group. Negative XM (NXM) was defined by a negative standard XM and a Tcell < +19mcs and a Bcell < +30mcs on FCXM. Patients who converted to NXM after desensitization comprised the converted group. The primary endpoint is difference in mean GFR at 3 mos, 6 mos, 1 yr, and 3 yrs. Other outcome measures include: survival, rejection episodes, infection.
Results: 108 patients were desensitized prior to PXM renal transplant. 42 failed to convert to negative FCXM (PXM group) prior to transplantation. Control (converted) group consisted of 66 patients.
Conclusions: GFR was significantly lower in the PXM group compared to the converted group at discharge and 1 yr. A significantly higher percentage of the PXM group had a GFR< 30 mL/min at 1 yr. Numerically higher rates of BPAMR, BPACR, empiric rejection were seen in the PXM group, and a significantly higher incidence BPACR was seen in the positive final B cell FCXM subgroup versus those who converted to negative B cell FCXM at 1 yr. However, 1 and 3 yr graft and patient survival remained comparable. Opportunistic infections were also similar between groups.
To cite this abstract in AMA style:Patel S, Joseph J, Akkina S, West-Thielke P, Thielke J, Oberholzer J, Benedetti E. Outcomes Following Positive Crossmatch Renal Transplantation Despite Failure To Convert to Negative Flow Crossmatch after Desensitization [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/outcomes-following-positive-crossmatch-renal-transplantation-despite-failure-to-convert-to-negative-flow-crossmatch-after-desensitization/. Accessed July 5, 2020.
« Back to 2013 American Transplant Congress